Upstream Bio (NASDAQ:UPB) Reaches New 1-Year Low – What’s Next?

Upstream Bio, Inc. (NASDAQ:UPB) hit a new 52-week low during mid-day trading on Saturday . The company traded as low as $10.24 and last traded at $10.39, with a volume of 206423 shares traded. The stock had previously closed at $10.77.

Wall Street Analysts Forecast Growth

UPB has been the topic of a number of analyst reports. Piper Sandler assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 5th. They set an “overweight” rating and a $75.00 target price on the stock. William Blair started coverage on Upstream Bio in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. began coverage on Upstream Bio in a research report on Tuesday, November 5th. They set an “overweight” rating and a $38.00 target price for the company. Finally, TD Cowen initiated coverage on Upstream Bio in a report on Tuesday, November 5th. They issued a “buy” rating on the stock.

Upstream Bio Stock Performance

The stock’s fifty day simple moving average is $17.55.

Upstream Bio (NASDAQ:UPB) last posted its earnings results on Thursday, November 7th. The company reported ($6.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($6.38). The company had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.83 million. On average, equities analysts expect that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Upstream Bio stock. Moody Aldrich Partners LLC acquired a new stake in shares of Upstream Bio, Inc. (NASDAQ:UPB) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 74,773 shares of the company’s stock, valued at approximately $1,229,000. Moody Aldrich Partners LLC owned about 0.14% of Upstream Bio as of its most recent SEC filing.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.